- Oral presentation
- Open Access
PINOT NOIR: Pulmonic INsufficiency imprOvemenT with Nitric Oxide Inhalational Response
© Hart et al; licensee BioMed Central Ltd. 2012
- Published: 1 February 2012
- Cardiac Magnetic Resonance
- Regurgitant Volume
- Pinot Noir
- Regurgitant Fraction
- Nitric Oxide Inhalational
Tetralogy of Fallot (TOF) repair and pulmonary valvotomy for pulmonary stenosis (PS) often lead to progressive pulmonary insufficiency (PI), right ventricular enlargement and dysfunction. This study assessed whether the pulmonary regurgitant fraction measured by cardiac magnetic resonance imaging (CMR) could be reduced by a selective pulmonary vasodilator.
Patients with at least moderate PI by echocardiography undergoing a clinically indicated CMR study were prospectively enrolled. Patients with a RV-PA conduit or residual pulmonic stenosis were excluded. Ventricular volume and blood flow sequences were obtained at baseline and after administration of 40ppm inhaled nitric oxide (iNO). Eleven Sixteen patients (11 with repaired TOF and 5 with repaired PS) completed the protocol with adequate data for analysis.
The median age [range] was 35 [19 - 46] years, BMI was 26±5 kg/m2 (mean ± standard deviation), 50% were women and 75% were in NYHA class I. Right ventricular end diastolic volume index for the cohort was 157±33 mL/m2, end systolic volume index was 93±20 mL/m2 and right ventricular ejection fraction was 40±6%. Baseline pulmonary regurgitant volume was 45±25 mL/beat and regurgitant fraction was 35±16%. During administration of iNO, regurgitant volume was reduced by an average of 6±9% (p=0.01) and regurgitant fraction was reduced by an average of 5±8% (p=0.02). No statistically significant changes were observed in stroke volume, ejection fraction or cardiac output for either the left or right ventricle.
iNO administration appears to reduce the regurgitant fraction in patients with at least moderate PI suggesting a potential role for selective pulmonary vasodilator therapy in these patients.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.